News | Breast Density | November 19, 2020

Volpara Health and DetectED-X Team Up to Improve Breast Density Assessment

Powerful online training tool improves accuracy to better inform clinical decisions

Radiologists around the world will have access to a first-of-its-kind online breast density training tool designed to improve radiologists' ability to correctly identify women's breast density categories to comply with the Breast Imaging-Reporting and Data System (BI-RADS), thanks to a collaboration between DetectED-X and Volpara Health. 

November 19, 2020 — Radiologists around the world will have access to a first-of-its-kind online breast density training tool designed to improve radiologists' ability to correctly identify women's breast density categories to comply with the Breast Imaging-Reporting and Data System (BI-RADS), thanks to a collaboration between DetectED-X and Volpara Health. 

"While we have seen tremendous advances in medical imaging and AI tools to improve the detection of breast cancer, varying levels of skill and experience among radiologists reading mammograms can contribute to interpretation errors and variations in assessing breast density. Such errors and variations can delay diagnosis and impact the effectiveness of the treatment of disease, which may have important clinical and economic implications," said Patrick Brennan, Ph.D., CEO DetectED-X and Chair, Diagnostic Imaging at the University of Sydney.

The new training module, DensityED, integrates key technologies from Volpara and DetectED-X. Volpara has provided breast density assessments for more than 13 million women in 39 countries. The world-leading, cloud-based education platform, BreastED from DetectED-X, is already transforming the results that radiologists achieve by lowering recall rates, and improving cancer detection by over 34%.

The new DensityED takes radiologists through test modules to rate more than 60 mammogram images of various levels of difficulty, and challenges radiologists to classify the images as BI-RADS breast density categories from A through D. DensityED provides immediate feedback on reading performance and highlights the density classifications made by the radiologists. The tool also provides feedback when the radiologists' classification differs from the classification by Volpara software, enabling radiologists to identify and correct errors. DensityED allows radiologists to compare their accuracy across the globe and regionally. At the end of the training, users receive continuing education credits. 

"DensityED will help radiologists improve their ability to correctly and consistently perform BI-RADS density assessment, which is becoming increasingly important in light of the personalization of screening and expected FDA density reporting regulations," said Ralph Highnam, Ph.D., founder and CEO of Volpara Health Technologies. "Accurate, reproducible density information is needed to empower women in their breast health journey."

A potential new federal regulation, proposed in February 2019, would require mammography facilities across the country to include whether a patient has dense breast composition in the report following her screening mammogram.

Joseph Russo, M.D., Section Chief for Mammography at St. Luke's University Health Network, who has tested the training module said, "This online educational tool comes at a critical time when radiologists are seeking more virtual continuing education opportunities. DensityED is an efficient way to improve accuracy and consistency in BI-RADS classification, which is a critical element in increasing the adoption of risk-based screening programs."

DensityED is available to Volpara customers in 39 countries and will be sold independently through DetectED-X. Through this partnership, Volpara will also make BreastED, DetectED-X's gold standard in radiologic breast cancer detection training, available to clinicians. Volpara's density software has been included in more than 300 peer-reviewed articles and research abstracts, and is the most clinically validated automatic, volumetric breast density assessment software in the field of breast cancer research.

For more information: www.volparahealth.com

Related Content

Radiologists have recently taken on the role of activists and are tackling pressing issues in healthcare, including breast density

Getty Images

Feature | Women's Health | January 20, 2021 | By Fazila Seker, Ph.D.
Radiologists — who have long been professionals in the metaphorical and literal back-rooms of healthcare — have recen
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant the

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant therapy shows new mass (arrow) in upper outer left breast that was assessed as BI-RADS 4. Pathologic examination from MRI-guided core biopsy of new suspicious mass revealed benign usual ductal hyperplasia. No atypia or malignancy was identified. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | MRI Breast | January 15, 2021
January 15, 2021 — According to ARRS' ...
A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

Getty Images

News | Mammography | January 14, 2021
January 14, 2021 — Completing cancer screening tests, such as...
DB-I website features new educational tools and streamlined user experience to improve access to medically sourced breast density content
News | Breast Density | January 13, 2021
January 13, 2021 — DenseBreast-info.org (DB-I) invites he
This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately
News | Mammography | January 12, 2021
January 12, 2021 — Therapixel announced that...
World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images

News | Mammography | January 06, 2021
January 6, 2021 — World-first techniques for predicting breast cancer risk from...
Transaction accelerates Hologic’s entry into oncology growth market, provides new lab capabilities

Getty Images

News | Breast Imaging | January 06, 2021
January 6, 2021 — Hologic, Inc., a global leader in women's...